Control-IQ Technology Continues to Demonstrate Positive and Sustained Real-World Benefits Across Diverse Cohorts of People with Diabetes
NEW ORLEANS, June 06, 2022–(Business WIRE)–Tandem Diabetes Treatment, Inc. (NASDAQ:TNDM), a world-wide insulin shipping and delivery and diabetic issues technologies enterprise, introduced beneficial true-environment facts demonstrating instant and sustained gains in a diverse cohort of men and women using the t:trim X2™ insulin pump with Regulate-IQ® know-how. The details was offered at the American Diabetes Affiliation (ADA) 82nd Scientific Periods in New Orleans.
“Our Command-IQ technological know-how carries on to be a excellent equalizer for people today with insulin-intense diabetes, as we persistently see beneficial scientific and top quality-of-lifestyle advancement with its use, regardless of age, ethnicity, or prior remedy,” claimed Jordan Pinsker, MD, Vice President and Professional medical Director for Tandem Diabetes Care. “This evidence will increase our commitment to deliver new innovations in technological innovation to reward people today living with diabetes all over the world.”
Facts presented at the conference arrives from the Command-IQ Observational (CLIO) research, an ongoing serious-environment, longitudinal study of individuals working with the t:slim X2 insulin pump with Command-IQ engineering.
Summaries of ADA Scientific Classes Presentations
Psychosocial Positive aspects of Employing Command-IQ Technologies: Long-term Outcomes from a Multi-Ethnic Grownup Cohort with Variety 1 Diabetes1
Named as an ADA Presidents’ Select Summary Presentation, this evaluation characteristics affected individual-described outcomes from an ethnically numerous cohort of 1,306 adults. Effects demonstrated significant enhancements in diabetes-specific high-quality of everyday living, gratification with insulin shipping machine, and reduction in diabetic issues-associated load over 12 months with Management-IQ engineering. Psychosocial advantages of Control-IQ technological know-how had been skilled by all ethnic cohorts. Noticeably enhanced quality of slumber was also observed for all contributors making use of the procedure.
Evaluation of Extensive-Phrase Glycemic Outcomes by Ethnicity in Grown ups with Type 1 Diabetes Applying Control-IQ Know-how2
This research assessed relationships among ethnicity, baseline HbA1c, Glucose Administration Indicator (GMI), and sensor Time in Variety (TIR) (70-180mg/dL) for 1,045 grownup CLIO members (Asian, Black/African American, White, and Hispanic/Latino/Spanish). GMI at study end mirrored glycemic advancements for all members, with Black/African American individuals displaying a clinically related .7% all round reduction.
Extended-phrase Glycemic Command in Grownup Individuals Utilizing Management-IQ Technological innovation: Authentic-World Evidence3
This review assessed baseline HbA1c and glucose management indicator derived from sensor details from 1,107 older people making use of Command-IQ technological know-how for 12 consecutive months. Details demonstrated sizeable glycemic advancements, regardless of prior therapy modality.
Numerous every day injection buyers with rather superior HbA1c values initiating Manage-IQ engineering confirmed dramatic and sustained glycemic improvements. Previous pump users also demonstrated rapid and sustained advancements, continuing to establish on proof that all end users can profit from Manage-IQ technological innovation irrespective of prior therapy.
“Demonstrating that our technology advantages ethnically diverse groups, irrespective of preceding therapy modality, is significant to fulfilling our mission to make improvements to the life of people residing with diabetic issues all over the world,” claimed Steph Habif, EdD, MS, Vice President, Behavioral Sciences at Tandem Diabetic issues Care. “As a worldwide chief in insulin treatment administration, we try to supply diabetic issues care options that get the job done equally nicely across all people living with diabetes, and the data introduced at this conference is proof of our results towards this purpose.”
References
1. Singh H, Alencar G, Sanchez H, et al. Psychosocial Added benefits of working with the t:slender X2 Insulin Pump with Management-IQ know-how: Very long-time period Outcomes from a Multi-ethnic Grownup Cohort with Sort 1 Diabetic issues. Oral presentation at 82nd Scientific Periods of the American Diabetes Association June 3-7, 2022 New Orleans, LA.
2. Habif S, Graham R, Singh H, et al. Evaluation of extensive-term glycemic outcomes by ethnicity in adults with variety 1 diabetes working with the t:trim X2 insulin pump with Command-IQ technologies. Poster introduced at 82nd Scientific Classes of the American Diabetic issues Affiliation June 3-7, 2022 New Orleans, LA.
3. Pinsker J, Graham R, Singh H, et al. Lengthy-expression Glycemic Manage in Grownup Individuals Working with the t:slender X2 Insulin Pump with Control-IQ Technology: True-Planet Evidence. Poster offered at 82nd Scientific Periods of the American Diabetic issues Association June 3-7, 2022 New Orleans, LA.
About Tandem Diabetic issues Care, Inc.
Tandem Diabetic issues Treatment, Inc., a global insulin delivery and diabetes technologies business based mostly in San Diego, California, produces new alternatives for people today residing with diabetic issues, their loved types, and healthcare suppliers via a positively distinct experience. The company’s human-centered tactic to style and design, enhancement, and help provides modern items and products and services for persons who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Management-IQ technological know-how. For more facts, take a look at tandemdiabetes.com.
Stick to Tandem Diabetes Care on Twitter @tandemdiabetes use #tslimX2, #ADA2022 and $TNDM.
Abide by Tandem Diabetes Care on Fb at fb.com/TandemDiabetes.
Observe Tandem Diabetes Treatment on LinkedIn at linkedin.com/organization/tandemdiabetes.
Dependable use of Command-IQ technological innovation
Manage-IQ know-how does not avert all highs and lows. Users should even now bolus for meals and actively manage their diabetes. Take a look at tandemdiabetes.com/safetyinfo for more important security information and facts.
Important Protection Information and facts: RX ONLY. The t:trim X2 pump and Management-IQ engineering are intended for single patient use. The t:slim X2 pump and Command-IQ technological know-how are indicated for use with NovoLog or Humalog U-100 insulin. t:slender X2 insulin pump: The t:trim X2 insulin pump with interoperable technological know-how is an alternate controller enabled (ACE) pump that is intended for the subcutaneous supply of insulin, at set and variable charges, for the administration of diabetes mellitus in men and women necessitating insulin. The pump is equipped to reliably and securely talk with compatible, digitally connected devices, which includes automatic insulin dosing computer software, to get, execute, and affirm instructions from these units. The t:slim X2 pump is indicated for use in individuals 6 many years of age and greater. Handle-IQ technologies: Command-IQ technological innovation is meant for use with a appropriate integrated constant glucose monitor (iCGM, sold individually) and ACE pump to immediately raise, minimize, and suspend shipping and delivery of basal insulin primarily based on iCGM readings and predicted glucose values. It can also produce correction boluses when the glucose value is predicted to exceed a predefined threshold. Handle-IQ engineering is supposed for the administration of Type 1 diabetes mellitus in folks six several years of age and greater.
BOXED WARNING: Regulate-IQ know-how should really not be made use of by anybody under the age of 6 years outdated. It need to also not be applied in clients who involve much less than 10 units of insulin per day or who weigh less than 55 lbs ..
Command-IQ engineering is not indicated for use in pregnant women, men and women on dialysis, or critically sick patients. Do not use Handle-IQ technology if applying hydroxyurea. Buyers of the t:slender X2 pump and Manage-IQ technological innovation should: use the insulin pump, CGM, and all other procedure elements in accordance with their respective guidelines for use examination blood glucose ranges as advisable by their health care service provider display satisfactory carb-counting capabilities sustain sufficient diabetes self-care abilities see healthcare company(s) frequently and have satisfactory eyesight and/or listening to to recognize all functions of the pump, which include alerts, alarms, and reminders. The t:trim X2 pump, and the CGM transmitter and sensor will have to be removed just before MRI, CT, or diathermy cure. Visit tandemdiabetes.com/safetyinfo for additional critical safety information and facts.
© 2022 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetic issues Treatment, Manage-IQ, and t:slender X2 are both registered logos or emblems of Tandem Diabetes Care, Inc. in the United States and/or other nations around the world. All third-occasion marks are the home of their respective owners.
Check out source model on businesswire.com: https://www.businesswire.com/information/home/20220606005878/en/
Contacts
Media Get hold of:
Steve Sabicer
714-907-6264
[email protected]
Trader Contact:
Susan Morrison
858-366-6900
[email protected]
